Carregant...
Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
BACKGROUND: National Comprehensive Cancer Network guidelines recommend monthly osteoclast inhibitor treatment (OIT) in men with metastatic castration-resistant prostate cancer (mCRPC) to prevent skeletal related events (SREs). We assessed adherence to guidelines by quantifying treatment for SRE prev...
Guardat en:
| Publicat a: | Clin Oncol Res |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2018
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6457685/ https://ncbi.nlm.nih.gov/pubmed/30984916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31487/j.COR.2018.03.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|